NCT06677918CompletedPhase 1
A randomised, double-blind, placebo-controlled trial to assess the effects of EP395 following an inhaled endotoxin challenge in healthy adults
Source: EU CTIS (euclinicaltrials.eu) · Last updated 26 Feb 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- First submitted
- 20 Sept 2024
- Start date
- 20 Feb 2025
- Lead sponsor
- EpiEndo Pharmaceuticals ehf.
- Diseases
- COPD
- NCT number
- NCT06677918
- EU CT number
- 2024-516187-29-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 65
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fraunhofer Institute for Toxicology and Experimental Medicine ITEM Coordinator of this site? Confirm its status | Hannover | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.